JNJ

174.13

+0.25%↑

ABBV

198.84

-0.12%↓

AZN

74.32

+0.36%↑

NVS

118.56

+0.28%↑

ABT

130.85

-2.14%↓

JNJ

174.13

+0.25%↑

ABBV

198.84

-0.12%↓

AZN

74.32

+0.36%↑

NVS

118.56

+0.28%↑

ABT

130.85

-2.14%↓

JNJ

174.13

+0.25%↑

ABBV

198.84

-0.12%↓

AZN

74.32

+0.36%↑

NVS

118.56

+0.28%↑

ABT

130.85

-2.14%↓

JNJ

174.13

+0.25%↑

ABBV

198.84

-0.12%↓

AZN

74.32

+0.36%↑

NVS

118.56

+0.28%↑

ABT

130.85

-2.14%↓

JNJ

174.13

+0.25%↑

ABBV

198.84

-0.12%↓

AZN

74.32

+0.36%↑

NVS

118.56

+0.28%↑

ABT

130.85

-2.14%↓

Search

Allogene Therapeutics Inc

Fechado

SetorSaúde

1.04

Visão Geral

Variação de preço das ações

24h

Atual

Mín

1.02

Máximo

1.05

Indicadores-chave

By Trading Economics

Rendimento

206K

-60M

Margem de lucro

272,450

Funcionários

226

EBITDA

-302K

-56M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+628.16% upside

Dividendos

By Dow Jones

Próximos Ganhos

13 de ago. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-15M

241M

Abertura anterior

1.04

Fecho anterior

1.04

Sentimento de Notícias

By Acuity

50%

50%

162 / 374 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Very Strong Bearish Evidence

Allogene Therapeutics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

11 de ago. de 2025, 17:49 UTC

Grandes Movimentos do Mercado

180 Life Sciences Stock Jumps on $156 Million Notes Sale

11 de ago. de 2025, 17:18 UTC

Grandes Movimentos do Mercado

Tiziana Life Sciences Rises After FDA Approves IND for Foralumab Trial

11 de ago. de 2025, 16:25 UTC

Ganhos

Correction to Constellation Software 2Q Revenue Rises, Profit Shrinks Article on Aug. 8

11 de ago. de 2025, 23:50 UTC

Conversa de Mercado

Nikkei May Rise as Yen Weakens -- Market Talk

11 de ago. de 2025, 23:42 UTC

Conversa de Mercado

Global Energy Roundup: Market Talk

11 de ago. de 2025, 23:42 UTC

Conversa de Mercado

Woodside's Share Price Implies Lofty Oil Price -- Market Talk

11 de ago. de 2025, 23:36 UTC

Conversa de Mercado

Gold Edges Higher on Likely Technical Recovery -- Market Talk

11 de ago. de 2025, 23:32 UTC

Conversa de Mercado

Argosy's New Bull Sees Sentiment Toward REITs Improving -- Market Talk

11 de ago. de 2025, 23:02 UTC

Conversa de Mercado

RBA Set to Lower OCR With New Forecasts in Focus -- Market Talk

11 de ago. de 2025, 20:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

11 de ago. de 2025, 20:37 UTC

Ganhos
Aquisições, Fusões, Aquisições de Empresas

Bakkt Holdings: Andy Main Will Step Dn as Co-CEO and Director, Effective Aug 11, and Akshay Naheta Will Assume Role of CEO >BKKT

11 de ago. de 2025, 20:37 UTC

Ganhos
Aquisições, Fusões, Aquisições de Empresas

Bakkt Holdings 2Q Rev $577.9M >BKKT

11 de ago. de 2025, 20:37 UTC

Ganhos
Aquisições, Fusões, Aquisições de Empresas

Bakkt Holdings: In Upcoming Qtr, Will Conduct Comprehensive Review of Cost Structure to Ensure We Are Optimized, Driving Synergies Across Business, and Accelerating Path to Profitability >BKKT

11 de ago. de 2025, 20:22 UTC

Ganhos

Exodus Movement: Assets 2,058 Units of Bitcoin Valued at $220.5M, 2,729 Units of Ether Valued at $6.8M, $58.1M in Cash and Cash Equivalents, USD Coin, Treasury Bills as of June 30 >EXOD

11 de ago. de 2025, 20:22 UTC

Ganhos

Exodus Movement: Monthly Active Users 1.5M at End 2Q, Unchanged From 1.5M as of June 30, 2024 >EXOD

11 de ago. de 2025, 20:22 UTC

Ganhos

Exodus Movement: Processed Volume $1.38B in 2Q Dn 37% From 1Q, Bitcoin, Tether (TRX Network), Tether (ETH Network), USDC, SOL Top Assets Traded in 2Q >EXOD

11 de ago. de 2025, 20:22 UTC

Ganhos

Exodus Movement: Digital Assets and Liquid Assets $291.2M >EXOD

11 de ago. de 2025, 20:22 UTC

Ganhos

Exodus Movement 2Q Rev $25.8M >EXOD

11 de ago. de 2025, 20:14 UTC

Conversa de Mercado

Canada Dollar Faces Near-Term Weakness on Trade Row, September Rate-Cut Chatter -- Market Talk

11 de ago. de 2025, 19:12 UTC

Conversa de Mercado

Crude-Oil Futures Edge Up in Rangebound Trade -- Market Talk

11 de ago. de 2025, 18:56 UTC

Conversa de Mercado

U.S. Natural-Gas Futures Fall on Forecast Loss of Late August Heat -- Market Talk

11 de ago. de 2025, 18:31 UTC

Conversa de Mercado

Mining Halt Could Lift Lithium Prices in Near Term -- Market Talk

11 de ago. de 2025, 17:43 UTC

Conversa de Mercado

Freeport-McMoRan Can Push Up Prices, Profits With Copper Tariff Protection -- Market Talk

11 de ago. de 2025, 17:28 UTC

Conversa de Mercado

Crossborder Trade Tensions Accelerate Softness in Canada Rents -- Market Talk

11 de ago. de 2025, 17:16 UTC

Conversa de Mercado

Commodity Longs Fall to 11-Month Low -- Market Talk

11 de ago. de 2025, 16:42 UTC

Aquisições, Fusões, Aquisições de Empresas

Adobe Stock Gets a Downgrade. 'AI Is Eating Software,' Analyst Says. -- Barrons.com

11 de ago. de 2025, 16:27 UTC

Aquisições, Fusões, Aquisições de Empresas

BBVA Says Sabadell Offer Remains in Effect

11 de ago. de 2025, 16:26 UTC

Aquisições, Fusões, Aquisições de Empresas

BBVA Previously Said It Won't Withdraw Offer to Buy Sabadell

11 de ago. de 2025, 16:25 UTC

Aquisições, Fusões, Aquisições de Empresas

Banco de Sabadell Announced TSB Sale on July 1

11 de ago. de 2025, 16:25 UTC

Aquisições, Fusões, Aquisições de Empresas

Banco de Sabadell Shareholders Approved TSB Unit Sale on Aug 6

Comparação entre Pares

Variação de preço

Allogene Therapeutics Inc Previsão

Preço-alvo

By TipRanks

628.16% parte superior

Previsão para 12 meses

Média 7.5 USD  628.16%

Máximo 14 USD

Mínimo 1 USD

Com base em 15 analistas de Wall Street que oferecem metas de preço de 12 meses para Allogene Therapeutics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

15 ratings

11

Comprar

4

Manter

0

Vender

Pontuação Técnica

By Trading Central

1.18 / 1.69Suporte e Resistência

Curto Prazo

Very Strong Bearish Evidence

Médio Prazo

Weak Bullish Evidence

Longo Prazo

Weak Bearish Evidence

Sentimento

By Acuity

162 / 374 Ranking em Saúde

Sentimento de Notícias

Neutral

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Allogene Therapeutics Inc

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.